A RETROSPECTIVE STUDY: THE OFF-LABEL USE OF ANTICONVULSANTS AT A PRIVATE HOSPITAL IN INDONESIA

  • Bangunawati Rahajeng Doctoral Student at Faculty of Pharmacy. Universitas Gadjah Mada, Yogyakarta 55281, Indonesia
  • Zullies Ikawati Pharmacology and Clinical Pharmacy Departement, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Tri Murti Andayani Pharmacology and Clinical Pharmacy Departement, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Iwan Dwiprahasto Pharmacology and Therapy Departement, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia

Abstract

Objective: Anticonvulsant is one class of drugs often used off-label. This study was conducted to investigate the prevalence and the indication of the off-label use of anticonvulsants in a private hospital in Java, Indonesia.

Methods: This was an observational study with a retrospective data collection in a private hospital in Java. Data were obtained on the prescription of anticonvulsants. Indications of the use of anticonvulsants were obtained from the medical records of patients who were prescribed anticonvulsants. The off-label use of anticonvulsants was defined a prescribing of medication outside the indication approved by The National Agency of Drug and Food Control Indonesia (NA-DFC). The use off-label of anticonvulsants was calculated by descriptive analysis and presented as a percentage.

Results: It showed that in one year there were 5,310 for 1,316 patients: of this 462 patients (35.11%) were for an off-label use. The anticonvulsants used off-label were oxcarbazepine 67.27% (37/55), carbamazepine 46.15% (54/117), pregabalin45.45% (60/132), phenytoin37.62% (225/598), valproate 25.34% (37/109), and gabapentin 18.28% (49/219). The highest off-label use of anticonvulsants was found in neurological and psychiatric disorders 67.32% (n=311), and on 97.19% of them were not supported by strong clinical evidence.

Conclusion: The off-label use of anticonvulsants occurred in one-third of patients receiving prescriptions of anticonvulsants, even though for most of them there was a lack of evidence. More attention must be paid to the efficacy and risk of side effects of the drug used.

Keywords: Anticonvulsants, Off-label, Private hospitals, Evidence-based medicine, Safe-prescribing

Downloads

Download data is not yet available.

References

Le Jeunne C, Billon N, Dandon A. Participants of roundtable N ° 3 of Giens XXVIII:, Berdaï D, Adgibi Y, et al. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? Therapie 2013;68:233–9.
2. Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N. Engl J Med 2008;358:1427–9.
3. Zito JM, Safer DJ, Gardner JF, Soeken K, Ryu J. Anticonvulsant treatment for psychiatric and seizure indications among youths. Psychiatr Serv [Internet] 2006; Available from: http://ps.psychiatryonline.org/doi/abs/10.1176/ps.2006.57.5.681. [Last accessed on 12 Oct 2016].
4. Chen H, Deshpande AD, Jiang R, Martin BC. An epidemiological investigation of off‐label anticonvulsant drug use in the georgia medicaid population. Pharmacoepidemiol Drug Saf 2005; 14:629–38.
5. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain [Internet]. In: The Cochrane Collaboration. editor. Cochrane Database of Systematic Reviews. Chichester. UK: John Wiley and Sons, Ltd; 2013. Available from: http://doi.wiley.com/10.1002/14651858.CD007963.pub2. [Last accessed on 20 Nov 2015]
6. Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 2014;10:537-46.
7. Presiden RI. Undang-undang Republik Indonesia No. 40 Tahun 2004 tentang Sistem Jaminan Sosial Nasional-[PERATURAN]; 2004.
8. Kesehatan IK. Peraturan Menteri Kesehatan Republik Indonesia Nomor 71 Tahun 2013 Tentang Pelayanan Kesehatan Pada Jaminan Kesehatan Nasional-[PERATURAN]; 2013.
9. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage 2003;25:S31–5.
10. Gomez-Arguelles JM, Dorado R, Sepulveda JM, Herrera A, Gilo Arrojo F, Aragón E, et al. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. J Clin Neurosci 2008;15:516–9.
11. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain Lond Engl 2005;9:543–54.
12. Raj V, Landess JS, Martin PR. Oxcarbazepine uses in essential tremor. PubMed-NCBI. Ann Pharmacother 2006;40:1876–9.
13. Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J. Oxcarbazepine in a migraine headache a double-blind, randomized, placebo-controlled study. Neurology 2008;70:548–55.
14. Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci 2007;28:156–8.
15. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029–37.
16. Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatr Dis Treat 2007;3:885.
17. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 2011;27:185–93.
18. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults [Internet]. In: The Cochrane Collaboration. editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley and Sons, Ltd; 2009. Available from: http://doi.wiley.com/10.1002/ 14651858.CD007076.pub2. [Last accessed on 26 Feb 2015]
19. Singla, Chelly J, Lionberger D, Gimbel J, Sanin L, Sporn J, et al. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res 2014;8:9-20.
20. Sjolund KF, Yang R, Lee KH, Resnick M. Randomized study of pregabalin in patients with cancer-induced bone pain. Pain Ther 2013;2:37–48.
21. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014;5:38-56.
22. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine. Neurochem Res 2002;27:121–30.
23. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267–84.
24. Jia H, Li Q, Song D, An Z, Liu Y, Ran X, et al. Effects of veniafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized,double-blind and double-dummy, controlled multi-center trial. Chin J Evid Based Med 2006;6:321–7.
25. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults [Internet]. In: The Cochrane Collaboration. editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley and Sons, Ltd; 2011. Available from: http://doi.wiley.com/10.1002/14651858. CD005451. pub2. [Last acessed on13 Oct 2016].
26. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain Lond Engl 2002;6 Suppl A:61–8.
27. Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults [Internet]. In: The Cochrane Collaboration. editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley and Sons, Ltd; 2012. Available from: http://doi.wiley.com/10.1002/14651858. CD009485.pub2. [Last accessed on 05 Mar 2015]
28. Tracy Glauser, Elinor Ben-Menachem, Blaise Bourgeois, Avital Cnaan, Carlos Guerreiro, Reetta Ka, et al. Guidelines-epilepsia-12074-2013.pdf. Epilepsia; 2013. p. 1–13.
29. Vargas Espinosa M, Sanmarti Garcia G, Vazquez Delgado E, Gay Escoda C. Antiepileptic drugs for the treatment of neuropathic pain: a systematic review. Med Oral Patol Oral Cirugia Bucal 2012;17:e786–93.
30. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults [Internet]. In: The Cochrane Collaboration. editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley and Sons, Ltd; 2011. Available from: http://doi.wiley.com/ 10.1002/14651858.CD009183.pub2. [Last accessed on 05 Mar 2015].
31. Horowitz E, Bergman LC, Ashkenazy C, Moscona Hurvitz I, Grinvald Fogel H, Magnezi R. Off-label use of sodium valproate for schizophrenia. PLoS One 2014;9:e92573.
32. Chang CY, Challa CK, Shah J, Daniel E. Gabapentin in acute postoperative pain management. BioMed Res Int; 2014. p. 1–7.
33. McCleane GJ. Gabapentin reduces chronic benign nociceptive pain: a double-blind, placebo-controlled cross-over study. Pain Clin 2000;12:81–5.
34. Jena SS, Jena M, Patro N, Mishra S, Panda M, Dash M. Patterns of prescription and adr monitoring of drugs in the management of neuropathic pain in a tertiary care teaching hospital. Int J Pharm Pharm Sci 2014;6:246–51.
35. Varghese AP, Philip B, Krihnakumar M, Kuriakose F, Rodrigues PA. Assessment of osteoporosis and anaemia risk in patients on anticonvulsant therapy. Int J Pharm Pharm Sci 2016;8:404–8.
Statistics
468 Views | 522 Downloads
Citatons
How to Cite
Rahajeng, B., Z. Ikawati, T. M. Andayani, and I. Dwiprahasto. “A RETROSPECTIVE STUDY: THE OFF-LABEL USE OF ANTICONVULSANTS AT A PRIVATE HOSPITAL IN INDONESIA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 10, no. 5, May 2018, pp. 119-22, doi:10.22159/ijpps.2018v10i5.25388.
Section
Original Article(s)